Studies have shown that disease‐free survival (DFS) may be longer among patients with resected NSCLC with EGFR mutation who receive adjuvant first‐generation EGFR‐TKIs than among those who receive adjuvant chemotherapy or placebo.15, 16. Here, EGFR is linked to non-small cell lung carcinoma.